1. Dr. Reddy's reported ₹85.1 billion in revenues, with a 20% YoY growth. 2. Successful product launches contributed to double-digit growth in multiple markets. 3. Partnerships in biosimilars expected to enhance market presence in the U.S. and Europe. 4. Gross margins declined due to pricing pressure in generics and rising costs. 5. RSY's successful year highlights potential for sustainable future growth.
Double-digit growth and new partnerships suggest potential revenue increase. Past growth strategies often lead to stock price appreciation.
Strong revenue growth and strategic initiatives highly relevant to investors and market analysts.
Partnerships and product launches indicate sustained growth, particularly in biosimilars, contributing to long-term revenue.
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).
|
Q4FY25 |
FY25 |
|||
| Revenues |
₹ 85,060 Mn |
₹ 325,535 Mn |
||
|
[Up: 20% YoY^; 2% QoQ] |
[Up: 17% YoY^] |
|||
| Profit for the Period | ₹ 15,939 Mn |
₹ 56,544 Mn |
||
|
attributable to Equity Holders |
[Up: 22% YoY; 13% QoQ] |
[Up: 2% YoY] |
Commenting on the results, Co-Chairman & MD, G V Prasad said: "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities.”
| All amounts in millions, except EPS | |
|
All US dollar amounts based on convenience translation rate of 1 USD = ₹85.43 |